Novartis and Experimental Cardiovascular Drugs Face Setbacks in Clinical Trials
Sourced from 5 publications
- •A new drug expected to lower heart attack risk proved no better than a placebo in recent trials.
- •Novartis's drug lowered a cardiovascular risk marker but failed to reduce heart attack or stroke risk.
- •The findings present a challenge to underlying assumptions in cardiovascular drug research.
What Happens Next
- →Investment in cardiovascular drug research decreases as investors reevaluate their strategies.
- →Competing pharmaceutical companies may accelerate the development of alternative cardiovascular therapies to capture market share.
- →Insurance companies potentially reassess their coverage policies for similar cardiovascular treatments.
Near-term: Funding for Novartis's specific drug development ventures may decline. Long-term: The industry potentially shifts towards multi-target approaches or personalized medicine as a structural change.
Sources
How Cardiologists’ High Hopes for Two Drugs Were Dashed
New York Times
Kardigan, Inc. (KARD) Discusses Aortic Stenosis Progression Data and KATALYST-AV...
Seekingalpha
A promising new medicine against heart disease fails unexpectedly
NPR News
New pill hailed as 'Holy Grail' could cure high blood pressure
Dailymail
Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
Statnews
Curated from 5 sources. Every summary is reviewed for accuracy, but may still contain errors. We always link to original sources for verification.
Related Stories
About Meridian
Meridian is a free daily newsletter delivering signal-scored news stories with forward-looking analysis every morning. Stories are scored across six criteria (global leverage, capital impact, temporal durability, career relevance, decision utility, and narrative clarity) then assigned to Big Signal, Core, or Quick tiers.
Get Meridian in your inbox
The stories that matter, every morning at 06:00.